Bristol-Myers Squibb Company (BMY MX) stock market data APIs
₱941.1371
-16.6(-1.8%)
as of December 3, 2025
Try our APIs with
free plan!
Bristol-Myers Squibb Company Financial Data Overview
Price chart is built with
Anychart
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Prev. Close
941.1371
Open
924.5402
High
945.9684
Low
902.1037
52 wk Range
784.8826-1215.0993
Market Cap
1 911 572 M
P/E Ratio
17.2547
Shares Outstanding
2 036 M
Revenue
48 034 M
EPS
20.1084
Dividends (Yield)
0.0028
Beta
0.309
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bristol-Myers Squibb Company data using free add-ons & libraries
Get Bristol-Myers Squibb Company Fundamental Data
Bristol-Myers Squibb Company Fundamental data includes:
- Net Revenue: 48 034 M
- EBITDA: 19 217 M
- Earnings Per Share: 54
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 1.52
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bristol-Myers Squibb Company News
New
Bristol-Myers Stock Rises on Alzheimer’s Drug Study Update
Bristol-Myers Squibb shares rallied Wednesday after the drugmaker delayed the release of eagerly awaited clinical-trial results for a potential Alzheimer’s disease treatment. Analysts said investors...
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
Success demonstrates the power of EMMI, Terray’s proprietary AI platform integrated with its rapidly expanding 13B+ target-ligand binding database and highly automated lab LOS ANGELES, December 03,...
Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock
Bristol Myers Squibb stock popped Wednesday after the firm delayed a study testing Cobenfy in Alzheimer's disease psychosis. Continue Reading
Bristol Myers Squibb Stock Climbs on Alzheimer’s Trial Update. What to Know.
The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease. Continue Reading
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
